

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	· FILIN	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/767,712	712 01/29/2004		Steven J. Coats	ORT 1375 CIP	5675
27777	7590	08/22/2005		EXAMINER	
	JOHNSON & JOHNSON	,	KIFLE, BRUCK		
		NSON PLAZA	•	ART UNIT	PAPER NUMBER
NEW BRUNSWICK, NJ 08933-7003				1624	
				DATE MAILED: 08/22/2009	5

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	<del>- 6</del>			
		10/767,712	COATS ET AL.				
Offi	ce Action Summary	Examiner	Art Unit				
		Bruck Kifle, Ph.D.	1624				
The M. Period for Reply	AILING DATE of this communication app		correspondence address				
THE MAILING  - Extensions of time after SIX (6) MO  - If the period for received for received to reply we have reply received.	ED STATUTORY PERIOD FOR REPLY DATE OF THIS COMMUNICATION. The may be available under the provisions of 37 CFR 1.13 NTHS from the mailing date of this communication. Beply specified above is less than thirty (30) days, a reply reply is specified above, the maximum statutory period within the set or extended period for reply will, by statute, and by the Office later than three months after the mailing man adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a Cause the application to become ABANDONE	nely filed  rs will be considered timely. Ithe mailing date of this communication (35 U.S.C. § 133).	ion.			
Status							
1)⊠ Respon	sive to communication(s) filed on 29 Ja	nuary 2004.					
		action is non-final.					
3)☐ Since th	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	n accordance with the practice under E	-					
Disposition of Cl	laims						
4)⊠ Claim(s	) <u>1-34</u> is/are pending in the application.						
	ne above claim(s) is/are withdrav						
	) is/are allowed.						
<u> </u>	) <u>1-34</u> is/are rejected.						
	) is/are objected to.		•				
	) are subject to restriction and/or	election requirement.					
Application Pape	ers						
_	cification is objected to by the Examine	•					
	ving(s) filed on is/are: a) ☐ acce		Evaminer				
	t may not request that any objection to the	•					
	ment drawing sheet(s) including the correcti	- · · ·	* *	(d)			
	or declaration is objected to by the Ex			(u).			
			7.00.017 07 1011117 10 102.				
Priority under 35	U.S.C. § 119						
12) Acknowl	edgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	)-(d) or (f).				
a)∏ All b	o)☐ Some * c)☐ None of:						
1.□ C	ertified copies of the priority documents	s have been received.					
2.□ C	ertified copies of the priority documents	s have been received in Applicati	on No				
	opies of the certified copies of the prior		ed in this National Stage				
	oplication from the International Bureau	· · · ·					
* See the a	ttached detailed Office action for a list of	of the certified copies not receive	ed.				
Attachment(s)		•					
1) Notice of Refere	ences Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Drafts	person's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	nte				
3)   Information Disc Paper No(s)/Ma	closure Statement(s) (PTO-1449 or PTO/SB/08) il Date 1/29/04.	5)  Notice of Informal P 6)  Other:	atent Application (PTO-152)				
J.S. Patent and Trademark Offic PTOL-326 (Rev. 1-04)		•	rt of Paper No./Mail Date 20050	817			

MC

Application/Control Number: 10/767,712

Art Unit: 1624

## Claim Rejections - 35 USC § 112

Claims 1-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- i) The last phrase of claims 1-3 reads "and pharmaceutically acceptable enantiomers, diastereomers and salts thereof." This is improper. Applicants may rewrite this phrase as "or enantiomers, diastereomers or pharmaceutically acceptable salts thereof." The claim should be rewritten using alternative language to be of proper Markush form.
- ii) The term "cycloalkyl" is indefinite because it is not known how many atoms make up the ring and what kind of a ring is intended (monocyclic, bicyclic, spiro, fused, bridged, saturated, etc.).
- iii) The term "heteroaryl" is indefinite because it is not known how many atoms are present, how many and what kind of heteroatoms are involved, what size ring is intended and how many rings are present.
- iv) The term "heterocyclyl" is indefinite because it is not known how many atoms make up the ring, which atoms are present and what kind of a ring (monocyclic, bicyclic, spiro, fused, bridged, saturated, etc.) is intended.

## Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

Page 2

Art Unit: 1624

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-34 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 6,552,036. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claimed compounds and patented compounds overlap substantially. The instant claims differ from the patented claims by reciting specific species and a more limited genus. It would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the patent, including those instantly claimed, because the skilled artisan would have the reasonable expectation that any of the species of the genus would have similar properties and, thus, the same use as taught for the genus as a whole. One of ordinary skill in the art would have been motivated to select the claimed compounds from the genus in the patent since such compounds would have been suggested by the patent as a whole.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle, Ph.D. whose telephone number is 571-272-0668. The examiner can normally be reached Tuesdays to Fridays between 8:30 AM and 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bruck Kifle, Ph.D. Primary Examiner Art Unit 1624

BK

August 17, 2005